ClearanceBrief
Recall Z-2638-2017 ยท NIG System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer

Beckman Coulter Inc.

Access System-GI Monitor (CA19-9), A83873D, Catalog No. 387687

DateMay 9, 2017
StatusTerminated
ReasonThe Access immunoassays are susceptible to biotin interference.
Root causeDevice Design
ActionAn urgent Medial Device Recall letter dated 5/9/17 was sent to customers to inform them that Beckman Coulter is initiating a field action for Access Total T3, Access Thyroglobulin, Access Free T4, and Access GI Monitor. Beckman Coulter has determined through customer feedback and an internal investigation that the four Access immunoassays listed above are susceptible to biotin interference. During interference testing the interference occurred with samples that contained 100 ng/mL of biotin. This level of biotin is greater than the maximum biotin concentration observed in the normal healthy
Quantity249,597 units total (9,388 units in US)
DistributionAlgeria, Angola, Australia, Austria, Bangladesh, Belgium, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Djibouti, Ecuador, Egypt, El Salvador, Estonia, Ethiopia, Finland, France, Georgia, Ger
FDA recordOpen on fda.gov

510(k) clearances named in this recall

K033038GI MONITOR AND GI MONITOR CALIBRATORS ON THE ACCESS IMMUNOASSAY SYSTEMS, MODEL 387687, 387688
Beckman Coulter, Inc., Dec 29, 2003